Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Oversight Of Clinical Trials Could Be Strengthened After Avandia Report

Executive Summary

FDA's oversight of clinical trials didn't reach the headlines during coverage of the Senate Finance Committee's report on Avandia safety, but pressure on the agency from Sens. Max Baucus, D-Mont., and Chuck Grassley, R-Iowa, could have far-reaching consequences for how industry conducts research for products in the future

You may also be interested in...



GSK Settles Hundreds Of Avandia Suits Before FDA Advisory Cmte. Meeting

The upcoming FDA advisory committee meeting on Avandia (rosiglitazone) may be putting pressure on GlaxoSmithKline to settle a chunk of the product liability suits facing the company

GSK Settles Hundreds Of Avandia Suits Before FDA Advisory Cmte. Meeting

The upcoming FDA advisory committee meeting on Avandia (rosiglitazone) may be putting pressure on GlaxoSmithKline to settle a chunk of the product liability suits facing the company

CDER Ombudsman Referees Increasing Number Of Internal Scientific Disputes

Last year, Virginia Behr, the ombudsman for FDA's Center for Drug Evaluation and Research, dealt with the usual consumer and industry complaints about off-label drug promotion, marketing of unapproved drugs and unethical research conduct. But she also played a greater role mediating scientific disputes between FDA staff

Related Content

Topics

UsernamePublicRestriction

Register

PS051971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel